Cure8 research brief
This real-world, multicenter study suggests risankizumab can induce clinical and steroid-free remission and mucosal healing in many patients with Crohn disease who previously failed advanced therapies, which may be relevant when considering treatment options after prior biologic/small-molecule failure.
Adult patients with Crohn disease, patients on or considering biologics/advanced therapies, gastroenterologists, and researchers studying IL-23 inhibitors or real-world treatment outcomes.
This is a retrospective, multicenter observational study (abstract-level summary) describing outcomes of risankizumab in routine care rather than a randomized trial. Clinical remission rates at the longest follow-up were higher when risankizumab was used as second-line advanced therapy compared with later lines, and most adverse events were mild.
The study reports steroid-free remission, clinical response, and endoscopic healing (in a subset with endoscopy data). A small number of patients required surgery during follow-up. Safety events were reported in about 12.6% of patients, most mild.
Because this summary is based on the article abstract, details such as patient selection, concomitant medications, exact definitions, and longer-term safety require reading the full paper.
Findings come from a retrospective multicenter cohort (abstract-level data). Observational design and partial endoscopic sampling limit causal conclusions; check the full paper for detailed methods, baseline characteristics, concomitant treatments, and longer-term safety.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: The authors have no conflicts of interest to declare.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.
